Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ELITE PHARMACEUTICALS INC /NV/ELTP · Entity 5936 | Chief Commercial Officer | July 10, 2025 | July 25, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ELITE PHARMACEUTICALS INC /NV/
Report date July 10, 2025 · Filed July 25, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 16,366 |
Reported balance
After 2025-07-10 transaction · row 1
1 source rowRow 1 · 2025-07-10 · Purchase · Acquired 16,366 · Balance 16,366 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 10, 2025 Filed Jul 25, 2025 22:05 UTC | ELITE PHARMACEUTICALS INC /NV/ ELTP · Entity 5936 | PurchaseCommon Stock | 16,366 | $0.59 | $9,639.57 |
DisclosureSEC source: 0001946043-25-000002 · primary_doc.xml · nonDerivative · entry 1 Kirkov Kirko · CIK 0001946043 · Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,366 Read SEC document |
| September 06, 2022 Filed Nov 14, 2022 16:10 UTC | ELITE PHARMACEUTICALS INC /NV/ ELTP · Entity 5936 | GrantOptions · Derivative | 3,000,000 | $0.04 Strike: $0.04 | $105,000.00 |
DisclosureSEC source: 0001946043-22-000003 · primary_doc.xml · derivative · entry 1 Kirkov Kirko · CIK 0001946043 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000,000 Underlying: Common Stock · 3,000,000 shares Expires 2032-09-06 F1 · shares: The Board of Directors approved and awarded options on November 10, 2022, as part of Mr. Kirkov's employment agreement dated September 6, 2022. F2 · derivative.exercise_date: The options will vest over a three-year period, commencing one year from the date of issuance. The first third will vest on September 6, 2023. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.